1. Antibody-drug Conjugate/ADC Related Vitamin D Related/Nuclear Receptor Metabolic Enzyme/Protease
  2. Antibody-Drug Conjugates (ADCs) ROR
  3. BL20-MMAE

BL20-MMAE 是由 BL20 连接子与 Auristatin 类载荷 MMAE (HY-15162) 结合的偶联物。BL20-MMAE 通过 BL20 连接子能够连接抗 ROR1 抗体,发挥抗癌活性。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

BL20-MMAE

BL20-MMAE Chemical Structure

CAS No. : 2765612-38-0

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

查看 ROR 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

BL20-MMAE is an antibody-drug conjugate targeting ROR1, which is formed by conjugating an anti-ROR1 antibody with the Auristatin payload MMAE (HY-15162) via a BL20 linker[1].

体外研究
(In Vitro)

BL20-MMAE (10 mg/mL; 28°C) 可与 ROR1-4 抗体偶联,形成药物抗体比精确为 4.0 的纯化抗体药物偶联物 (ADC)[1]
BL20-MMAE (10 mg/mL; 28°C) 可与 ROR1-12 抗体偶联,形成药物抗体精准比值为 4.0 的纯化 ADC[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

BL20-MMAE (以 ROR1-12-BL20E 形式给药) (5 mg/kg;静脉注射;第 0 天和第 4 天) 可在 JeKo-1 白血病异种移植模型中实现 92%的肿瘤生长抑制率,6 只小鼠中有 1 只出现肿瘤部分消退[1]
BL20-MMAE (以 ROR1-12-BL20E 形式给药) (5 mg/kg;静脉注射;每周 1 次;共 3 剂) 对 MDA-MB-231 乳腺癌异种移植物的肿瘤生长抑制率达 49%[1]
BL20-MMAE (以 ROR1-4-BL20E 形式给药)(5 mg/kg;静脉注射;每周 1 次;共 3 剂) 在 MDA-MB-231 乳腺癌异种移植模型中实现 39% 的肿瘤生长抑制[1]
BL20-MMAE (以 ROR1-12-BL20E 形式给药) (5 mg/kg;静脉注射) 在 H1975 非小细胞肺癌异种移植物中实现 51% 的肿瘤生长抑制[1]
BL20-MMAE (以 ROR1-4-BL20E 形式给药)(5 mg/kg;静脉注射) 可在 H1975 非小细胞肺癌异种移植模型中实现 69% 的肿瘤生长抑制[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: tumor-bearing mice (implanted with JeKo-1 cells, tumors grown to ~100 mm3)[1]
Dosage: 5 mg/kg
Administration: i.v.; on day 0 and day 4
Result: Achieved a tumor growth inhibition (TGI) rate of 92% in JeKo-1 tumors by day 18, with 1 out of 6 mice showing partial tumor regression.
Resulted in a statistically significant reduction in tumor volume compared to solvent control (P < 0.0001).
Animal Model: tumor-bearing mice (implanted with MDA-MB-231 cells)[1]
Dosage: 5 mg/kg
Administration: i.v.; once weekly; 3 doses
Result: Achieved a tumor growth inhibition (TGI) rate of 49% in MDA-MB-231 tumors.\nAchieved a tumor growth inhibition (TGI) rate of 39% in MDA-MB-231 tumors.
Animal Model: tumor-bearing mice (implanted with H1975 cells, tumors grown to 100-150 mm3)[1]
Dosage: 5 mg/kg
Administration: i.v.
Result: Achieved a tumor growth inhibition (TGI) rate of 51% in H1975 tumors.\nAchieved a tumor growth inhibition (TGI) rate of 69% in H1975 tumors.
分子量

1963.30

Formula

C98H133F2N13O23S2

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
BL20-MMAE
目录号:
HY-177109
需求量: